Effects of Melatonin on Glucose Homeostasis, Antioxidant Ability, and Adipokine Secretion in ICR Mice with NA/STZ-Induced Hyperglycemia

Abstract

Diabetes is often associated with decreased melatonin level. The aim was to investigate the effects of different dosage of melatonin on glucose hemostasis, antioxidant ability and adipokines secretion in diabetic institute for cancer research (ICR) mice. Forty animals were randomly divided into five groups including control (C), diabetic (D), low-dosage (L), medium-dosage (M), and high-dosage (H) groups. Groups L, M, and H, respectively, received oral melatonin at 10, 20, and 50 mg/kg of BW (body weight) daily after inducing hyperglycemia by nicotinamide (NA)/ streptozotocin (STZ). After the six-week intervention, results showed that melatonin administration increased insulin level and performed lower area under the curve (AUC) in H group (p < 0.05). Melatonin could lower hepatic Malondialdehyde (MDA) level in all melatonin-treated groups and increase superoxide dismutase activity in H group (p < 0.05). Melatonin-treated groups revealed significant higher adiponectin in L group, and lower leptin/adiponectin ratio and leptin in M and H groups (p < 0.05). Melatonin could lower cholesterol and triglyceride in liver and decrease plasma cholesterol and low-density lipoprotein-cholesterol (LDL-C) in L group, and increase plasma high-density lipoprotein-cholesterol (HDL-C) in H group (p < 0.05). Above all, melatonin could decrease oxidative stress, increase the adiponectin level and improve dyslipidemia, especially in H group. These data support melatonin possibly being a helpful aid for treating hyperglycemia-related symptoms.

A Study on Effect of Melatonin in Dyslipidemia Caused by Experimentally Diabetes

“…There are some reports that hyperglycemia generally caused hypertriglyceridemia and hypercholesterolemia (48). The findings obtained from our study appear to be consistent with the data of researches conducted on the same subject (19,24,48). The positive changes observed in the plasma lipid parameters by the administration of melatonin are attributed to the reasons such as suppressed tissue lubrication (34,47), increased lipoprotein lipase activity and increased insulin sensitivity resulting in decreased a-c The difference between mean values with different superscripts in the same column is significant at the p<0.05 level 120 © 2019 Faculty of Sport Sciences, Selcuk University of lipolysis in adipose tissue (34).…”

The Effects and Mechanism of Quercetin Dietary Supplementation in Streptozotocin-Induced Hyperglycemic Arbor Acre Broilers

“…Various experimental diabetes models have been proved to induce animal characteristic function and structural changes. These models include rats and mice that become diabetic after the administration of alloxan and STZ [7,8]. A limited study has been reported in the area of AA broiler diabetes.…”

“…A limited study has been reported in the area of AA broiler diabetes. STZ is a DNA alkylating agent [8], and its intraperitoneal or intravenous injection caused marked infiltration of inflammatory cells and reduced insulin secretion leading to diabetes [9][10][11]. STZ may increase the production of ROS and inhibit enzyme activities related with the scavenging of free radical [12].…”

Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin‐induced diabetes in mice

“…Since agomelatine is a melatonergic receptor agonist, its effects on glucose homeostasis are expected to be at least in part similar to melatonin effects. Melatonin has been reported not to reduce fasting blood glucose in STZ diabetic rat models [29][30][31][32]. Contrarily, several researchers suggested that melatonin lowered fasting blood glucose in STZ-or alloxaninduced diabetic rat models [33][34][35].…”